The shadow of generic challenges has repeatedly loomed around copyright’s iconic drug, PDE5 Inhibitor, sparking questions about the outlook of connected drug holdings. While first years saw substantial profits, the exclusivity lapse has created the path for less expensive copies, potentially lowering revenue and creating a real hazard for stakeho